Introduction
============

The clinical entity of "atypical" pneumonia was recognized in the 1930s many years before the etiological agent was established ([@B60]). The term separated this entity of pneumonia from classical pneumococcal pneumonia due to its lack of response to available antibiotics and the distinct clinical presentation without typical lobar pneumonia and a less severe disease course. That is why the term "walking pneumonia" has been introduced to denote this mild form of pneumonia.

It was in a patient with "atypical" pneumonia in 1944, where *Mycoplasma pneumoniae* was first isolated from sputum in tissue culture by [@B31]. At that time, it was believed to be a virus because it was resistant to penicillin and sulfonamides and passed through bacteria-retaining filters. Experiments with Marine recruits and adult prisoners demonstrated that the so-called Eaton agent caused lower respiratory tract infections in humans ([@B21],[@B22]). In 1963, it was first cultured on cell-free medium and classified as *M. pneumoniae* ([@B20]; [@B18]). Today we know that mycoplasmas are prokaryotes that lack a cell wall and represent the smallest self-replicating organisms (**Figure [1](#F1){ref-type="fig"}**). With a size of 816,394 base pairs, the genome of *M. pneumoniae* is at least five times smaller than that of *Escherichia coli* ([@B47]). The absence of a cell wall and the specialized attachment organelle facilitate close contact with the host respiratory epithelium, which supplies the bacterium with the necessary nutrients for its growth and proliferation.

![***M. pneumoniae* morphology *in vitro*.** Scanning electron micrograph of *M. pneumoniae* strain Mac (subtype 2).](fmicb-07-00329-g001){#F1}

*Mycoplasma pneumoniae* causes both upper and lower respiratory tract infections, with community-acquired pneumonia (CAP) as the major burden of disease. Although *M. pneumoniae* infections are generally mild and self-limiting, patients of every age can develop severe and fulminant disease ([@B55]). *M. pneumoniae* can also cause extrapulmonary manifestations that affect almost every organ ([@B76]).

In children, *M. pneumoniae* infections were first reported in 1960 when 16% of 110 children with lower respiratory tract disease were tested positive by a fourfold rise in antibody titers against the Eaton agent ([@B19]). To date, it is known that the incidence of *M. pneumoniae* infections is generally higher in children than in adults ([@B39]). This review focuses on the characteristics of *M. pneumoniae* infections in children, and discusses simple clinical decision rules that may further aid clinicians in identifying patients at high risk for *M. pneumoniae* CAP.

Epidemiology
============

*Mycoplasma pneumoniae* is transmitted by respiratory droplets through close contact. The incubation period can be long from 1 up to 3 weeks. Outbreaks have been reported within families, schools, universities, institutions, camps, and military bases. Family members of index patients with acute respiratory infection and detection of *M. pneumoniae* in the upper respiratory tract were found positive in 15% by polymerase chain reaction (PCR) ([@B28]). Thereof, 75% were \<16 years of age and 44% did not develop any respiratory symptoms. At universities, the largest outbreak within 35 years in the U.S. was observed during September 1--December 4, 2012, where a total of 83 CAP cases were identified among students, and 12 out of 19 tested cases (63%) were positive for *M. pneumoniae* by quantitative real-time PCR ([@B16]).

Outbreaks appear mainly during *M. pneumoniae* epidemics that occur in 3--7 years cycles, in addition to a background endemic pattern ([@B49]). The most recent epidemic in Europe occurred in 2010--2012 with a peak incidence in Finland of 145/100,000 cases in 2011 ([@B81]; [@B50]). The cyclic occurrence of epidemics may be facilitated by a decreasing herd immunity and different *M. pneumoniae* genotypes circulating in the human population ([@B49]). The two major circulating genotypes, or subtypes, of *M. pneumoniae* are indicated as subtype 1 and 2. Differences between these subtypes in the amino acid sequence of the major adhesion protein P1 are believed to play a role in the epidemiology of infections with *M. pneumoniae* ([@B92]; [@B93]). The differences between the 169-kDa P1 proteins of subtype 1 and 2 isolates were found to be concentrated in two specific amino acid stretches within the protein. These regions are encoded by two DNA elements within the P1 gene, i.e., repetitive elements RepMP2/3 and RepMP4. The RepMP2/3 and RepMP4 are not unique to the P1 gene, but are also found at other sites within the bacterial genome ([@B91]). Homologous recombination events between these repetitive elements, which are similar to each other, but not identical, may form the basis of antigenic variation of the P1 protein of *M. pneumoniae* ([@B93]). While such recombination events may induce antigenic variation within subtype 1 or subtype 2 strains, *M. pneumoniae* strains cannot switch from one subtype to the other, as the entire set of RepMP elements found in one subtype differs significantly from those found in the other subtype. Moreover, changes in the proportion of the two subtypes of *M. pneumoniae* were not observed between 2003 and 2012 in Europe ([@B50]).

Infection
=========

Respiratory Disease
-------------------

Although CAP is the major burden of disease, milder clinical presentations of *M. pneumoniae* respiratory infections may be much more common than CAP. These include acute bronchitis and upper respiratory tract infections ([@B33], [@B35]). *M. pneumoniae* could be detected by PCR and/or serology in 24% of non-streptococcal pharyngitis cases ([@B35]).

It is estimated that 3--10% of children with *M. pneumoniae* respiratory infection develop CAP and that \<5% of CAP cases are severe enough to require hospitalization ([@B94]). Between 1963 and 1975, *M. pneumoniae* was detected by culture of respiratory specimens and/or a fourfold titer rise in complement fixation test (CFT) in 15--20% of radiologically confirmed CAP cases in Seattle, U.S. ([@B39]). In subsequent etiological studies, *M. pneumoniae* accounted for 4--39% of the isolates identified by PCR and/or serology in children with CAP admitted to the hospital ([@B53]; [@B82]; [@B6]; [@B72]). *M. pneumoniae* was first reported as the most common bacterial cause of CAP in children requiring hospitalization in a U.S. multicenter study from 2011 to 2012 in Nashville and Salt Lake City ([@B51]). In this study, *M. pneumoniae* could be detected by PCR in 178 (8%) out of 2179 cases with CAP, whereas *Streptococcus pneumoniae* was found in 79 cases (4%).

Manifest upper and/or lower respiratory tract infections with *M. pneumoniae* occur at all ages ([@B39]). Recent observations have indicated that *M. pneumoniae* has also a relatively high prevalence in the respiratory tract of children \<5 years ([@B82]; [@B41]). *M. pneumoniae* CAP, however, was reported to be most frequent among school-aged children from 5 to 15 years of age, with a decline after adolescence and tapering off in adulthood (**Figure [2](#F2){ref-type="fig"}**) ([@B39]). This notion was corroborated in the recent CAP study in the U.S., where *M. pneumoniae* was detected significantly more frequent in children ≥5 years of age than in younger children (19% vs. 3%) ([@B51]).

![**Detection of *M. pneumoniae* in community-acquired pneumonia (CAP) according to age group.** Infection was diagnosed by culture of respiratory specimens and/or a fourfold titer rise in complement fixation test (CFT). Adapted with permission from [@B39].](fmicb-07-00329-g002){#F2}

In addition to the presentation at school-age, children with CAP due to *M. pneumoniae* have been found to present with a significantly longer duration of fever compared with other children with CAP ([@B37]). Other symptoms that may be associated with *M. pneumoniae* CAP are the absence of wheeze and the presence of chest pain ([@B95]). However, there is still a paucity of high quality data regarding clinical signs and symptoms associated with *M. pneumoniae* infections. A recent Cochrane review therefore concluded that the absence or presence of individual clinical symptoms or signs cannot be used to help clinicians accurately diagnose *M. pneumoniae* in children and adolescents with CAP ([@B95]).

Pathogenic effects in the respiratory tract may be caused by *M. pneumoniae* either directly (by active infection), indirectly (by infection-induced immune mechanisms), or both ([@B76]). *M. pneumoniae* causes direct injury through the generation of activated oxygen. A potential candidate protein of *M. pneumoniae* that may be involved in causing direct damage to the respiratory tract is a pertussis toxin-like protein termed Community-Acquired Respiratory Distress Syndrome (CARDS) toxin ([@B54]; [@B9]). A recombinant version of the CARDS toxin has been shown to bind with high affinity to surfactant protein A and to exhibit mono-ADP ribosyltransferase and vacuolating activities, which causes disruption of the respiratory epithelium in animal models ([@B54]).

In addition to the direct damage resulting from infection by *M. pneumoniae*, the immunological response following infection generates inflammatory reactions that may cause pulmonary and extrapulmonary symptoms. More severe symptoms of CAP have been observed in older children and adolescents ([@B94]). This suggests that the age-dependent magnitude and nature of inflammatory responses in childhood may be a major factor contributing to the development of *M. pneumoniae*-associated disease, similar to what is observed, e.g., in infectious mononucleosis or rheumatic fever. In fact, the severity of *M. pneumoniae* CAP in children was closely associated with increased concentrations of interleukin (IL)-8 and IL-18 in acute phase serum and pleural fluid samples ([@B77]). In addition, it has been demonstrated that cell-mediated immunity contributes to the pathogenesis of *M. pneumoniae* CAP, as it was shown that the severity of CAP correlated positively with the size of a cutaneous induration following intradermal injection of *M. pneumoniae* antigens ([@B73]). This study described 20 patients with CAP, of which 19 were children 4--15 years of age, diagnosed by a significant rise in antibody titers against *M. pneumoniae* with CFT. The strongest skin reactions were seen in patients with severe CAP.

Asthma
------

*Mycoplasma pneumoniae* and other "atypical bacteria" have long been implicated in the pathogenesis of asthma ([@B4]). There are many studies that have addressed this issue in the recent past. In an observational study on children and adults with asthma, *M. pneumoniae* infection was diagnosed in 9% of children with asthma (24/256) and was found more frequent in patients with chronic asthma (14%) than in those with asthma exacerbations (7%; *p* = 0.10) ([@B8]). The diagnosis of *M. pneumoniae* infection in this study was performed by PCR and/or serology. Another recent study diagnosed *M. pneumoniae* in children with acute asthma (64%, 34/53) and refractory asthma (65%, 17/26), as well as in healthy controls (56%, 36/64), but did not find significant differences between these three groups ([@B96]). The high detection rates reported in this study were obtained using novel diagnostic methods \[CARDS toxin enzyme immunoassay (EIA) and CARDS gene-specific PCR\] ([@B96]). In a recent Taiwanese study ([@B97]), 1591 children and adults with *M. pneumoniae* infection, diagnosed by positive immunoglobulin (Ig) M or fourfold IgG titer increase, but without prior asthma history were included from 2000 to 2008 and followed until the diagnosis of asthma or the end of 2011. Compared to matched 6364 patients without *M. pneumoniae* infection, the cumulative incidence of asthma was significantly higher in the *M. pneumoniae* cohort than in the control cohort (*p* \< 0.0001). Patients with *M. pneumoniae* infection were at higher risk of having early-onset asthma (age at asthma diagnosis \<12 years) and late-onset asthma (age at asthma diagnosis ≥12 years). These most recent findings suggested that *M. pneumoniae* can induce airway inflammation and contribute to incident asthma. Interestingly, exposure to recombinant CARDS toxin resulted in an allergic-type inflammatory response and airway hyperreactivity in mice and baboons ([@B44]; [@B62]). It will be interesting to investigate whether CARDS toxins induce a similar allergic response during *M. pneumoniae* infections.

Extrapulmonary Manifestations
-----------------------------

Apart from the respiratory tract infection, *M. pneumoniae* can cause extrapulmonary manifestations in almost every organ, including the skin and the hematologic, cardiovascular, musculoskeletal, and nervous systems ([@B76]). These manifestations may be caused either by direct local effects of *M. pneumoniae*, after dissemination of the bacteria throughout the body, or indirect effects, such as autoimmune reactions. The most frequent manifestations are diseases of the dermatologic and nervous system.

Skin manifestations occur in up to 25% of all *M. pneumoniae* infections, including mostly non-specific exanthems, erythema nodosum, urticaria, Stevens--Johnson syndrome, and a rare but distinct disorder with prominent mucous membrane involvement denominated as *M. pneumoniae*-associated mucositis (MPAM) ([@B87]; [@B66]). This condition was first described by [@B40], and therefore also referred to as Fuchs syndrome ([@B65]). A recent review identified 32 patients with MPAM at a median age of 13.5 years at presentation (range 3--38 years, 23 children or young adolescents ≤18 years) ([@B66]). All patients presented with prodromal respiratory symptoms with a median duration of 7 days, and pneumonia was found in chest radiography in 79%. Oral lesions were present in all cases (**Figure [3](#F3){ref-type="fig"}**), ocular lesions in 97%, and urogenital lesions in 78%. There were no skin lesions in 69%. Although 12% of the patients were admitted to the intensive care unit, no one suffered from long-term sequelae.

![***M. pneumoniae*-associated mucositis (MPAM).** Erosive oral lesions limited to the mucosa in this form of MPAM in a 24-year-old woman. Reprinted with permission from [@B66].](fmicb-07-00329-g003){#F3}

Encephalitis and Guillain--Barré syndrome (GBS) constitute the most common and severe neurologic manifestations, where *M. pneumoniae* infection is established in up to 10 and 15% of patients, respectively ([@B11]; [@B88]). In *M. pneumoniae*-associated encephalitis, both a direct infection of the central nervous system (CNS) and an immune-mediated process have been implied to be involved ([@B75]). Because the detection rate of *M. pneumoniae* by PCR in cerebrospinal fluid (CSF) of *M. pneumoniae* encephalitis patients is relatively low (0--14%) ([@B11]; [@B26]; [@B24]; [@B27]), a significant proportion of the cases is believed to be immune-mediated. This is supported by the finding that various cases with *M. pneumoniae* encephalitis in which bacterial DNA could not be detected in CSF had a more prolonged duration of respiratory symptoms before the onset of encephalitis (\>5--7 days) ([@B11]; [@B78]; [@B26]). These cases indicate that *M. pneumoniae* encephalitis represents a postinfectious disorder, which manifests after clearance of the bacteria from the CNS or respiratory tract by the immune system ([@B68]). A recent study presented 365 children with *M. pneumoniae* detected in the respiratory tract or CSF by PCR, 22 (6%) of whom had encephalitis (1996--2013, Toronto, ON, Canada) ([@B2]). Interestingly, patients in which *M. pneumoniae* was detectable in the respiratory tract but not in CSF showed pulmonary infiltrates on chest radiograph more frequently than patients with positive PCR in CSF (77% vs. 33%). This suggests that pneumonia may be an indicator for a remote inflammatory process in *M. pneumoniae* encephalitis patients, which was also shown in 83% (5/6) of children observed during a national surveillance, all with negative PCR in CSF (2010--2015, Switzerland) ([@B69]) (**Figure [4](#F4){ref-type="fig"}**).

![***M. pneumoniae*-associated encephalitis.** Axial cranial magnetic resonance imaging (MRI) in two children with encephalitis during *M. pneumoniae* infection: **(A)** 5-year-old boy with hyperintensity and generalized edema of the right temporal lobe \[T1 weight MRI; patient 1 published in [@B69]\]. **(B)** 9-year-old boy with generalized edema of crus posterior of capsula interna \[T2 weight MRI; reprinted with permission from [@B70]\].](fmicb-07-00329-g004){#F4}

*Mycoplasma pneumoniae* expresses adhesion proteins and glycolipids that share structural homology with a variety of host cells (molecular mimicry) and may induce cross-reactive antibodies ([@B68]). In children with *M. pneumoniae* encephalitis, intrathecal antibodies directed against galactocerebroside (GalC) were found ([@B25]; [@B67]). Of note, all these patients had a negative PCR in CSF. GalC is a major glycolipid antigen in the myelin sheath of both the peripheral and CNS neurons ([@B63]). In fact, antibodies against *M. pneumoniae* infection have been found to cross-react with GalC in GBS patients ([@B56]; [@B3]). Moreover, anti-GalC antibodies caused demyelinating neuropathy in rabbits ([@B85]) and have been associated with demyelination in GBS ([@B3]), but also in encephalitis ([@B25]) and encephalomyelitis ([@B86]). The detection of intrathecal antibodies against *M. pneumoniae* and GalC may also be regarded as a promising new diagnostic tool for *M. pneumoniae*-associated CNS disease ([@B68], [@B71]).

Carriage
========

Like many other respiratory pathogens, *M. pneumoniae* can be carried asymptomatically in the respiratory tract ([@B38]). Recent studies have demonstrated that asymptomatic carriage of *M. pneumoniae* is highly prevalent. Detection rates of *M. pneumoniae* DNA in the respiratory tract of healthy children without respiratory symptoms were 21% in a Dutch study (2008--2011, Rotterdam, The Netherlands) ([@B89]) and 56% in a U.S. study (2009--2011, San Antonio, TX, U.S.) ([@B96]). Longitudinal sampling of *M. pneumoniae*--positive asymptomatic children demonstrated that *M. pneumoniae* can be present in the upper respiratory tract without causing disease, for up to 4 months ([@B89]). The prevalence of *M. pneumoniae* in the upper respiratory tract of asymptomatic children varied considerably between years and seasons. For example, asymptomatic carriage rates of 3% and 58% were reported in the spring of 2009 and the summer of 2010, respectively ([@B89]). These data suggest that carriage follows an epidemic pattern. It is tempting to speculate that this fluctuation in prevalence is related to the cyclic epidemics of *M. pneumoniae* infections. Apart from *M. pneumoniae*, children were found to simultaneously carry many pathogens in their nose and throat ([@B89]). These pathogens include the bacteria *S. pneumoniae*, *Staphylococcus aureus*, *Moraxella catarrhalis*, and *Haemophilus influenzae*, and the viruses influenza A/B, human metapneumovirus, respiratory syncytial virus, parainfluenzavirus, rhinovirus, coronavirus, bocavirus, and adenovirus. The simultaneous presence of two or more of these pathogens was detected in 56% of asymptomatic children ([@B89]).

In children with *M. pneumoniae* CAP, co-existence of *M. pneumoniae* with other pathogens has also been described ([@B53]; [@B72]), and was recently reported in 28% of the patients ([@B51]). The impact of co-infections in *M. pneumoniae* CAP on disease severity is not yet determined.

Diagnosis
=========

Diagnostic Tests
----------------

Because the mere presence of *M. pneumoniae* in the upper respiratory tract is neither indicative nor predictive for respiratory disease, the routine diagnostic procedures to detect acute respiratory infections with *M. pneumoniae* need to be reconsidered. An overview of diagnostic tests with their advantages and drawbacks is shown in **Table [1](#T1){ref-type="table"}**.

###### 

Overview of diagnostic tests for *M. pneumoniae*.

  Method                                               Test                                    Target/antigen                                                                    Antibodies                                 Specimen(s)                                                                     Performance                                            Value   Comments
  ---------------------------------------------------- --------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------ ------------------------------------------------------------------------------- ------------------------------------------------------ ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Direct identification of *M. pneumoniae*             Polymerase chain reaction (PCR)         Different target genes (e.g., P1 gene, 16S rDNA, 16S rRNA, RepMP elements etc.)   --                                         Respiratory specimen Cerebrospinal fluid (CSF) Other bodily fluids or tissues   High sensitivity, high specificity                     RD      \- Validation and standardization required for routine diagnostic ([@B58]); - Epidemiological differentiation of clinical strains on the basis of differences in the P1 gene by PCR ([@B91]) or in the number of repetitive sequences at a given genomic locus by multiple-locus variable-number tandem repeat analysis (MLVA) ([@B17]).
                                                       Culture                                 --                                                                                --                                         Respiratory specimen                                                            Low sensitivity, high specificity                      AD      \- Special enriched broth or agar media; - Isolation takes up to 21 days.
  Non-specific serological tests for *M. pneumoniae*   Cold agglutinin test ("bedside test")   Erythrocytes (I antigen)                                                          Cold agglutinins (IgM)                     Serum                                                                           Low sensitivity, low specificity                       --^1^   \- Cold agglutinins target the I antigen of erythrocytes; - Positive in only about 50% and in the first week of symptoms; - Less well studied in children; - Cross-reactivity with other pathogens and non-infectious diseases.
  Specific serological tests for *M. pneumoniae*       Complement fixation test (CFT)          Crude antigen extract with glycolipids and/or proteins                            Igs (no discrimination between isotypes)   Serum                                                                           Sensitivity and specificity comparable to EIA          --^1^   \- Positive criteria: fourfold titer increase between acute and convalescent sera or single titer ≥1:32; - Cross-reactivity with other pathogens and non-infectious diseases.
                                                       Particle agglutination assay (PA)                                                                                         IgM and IgG simultaneously                                                                                                                                                        --^1^   
                                                       Enzyme immunoassay (EIA)                Proteins (e.g., adhesion protein P1) and/or glycolipids                           IgM, IgG, IgA                              Serum CSF^2^                                                                    Moderate-high sensitivity, Moderate-high specificity   RD      \- The sensitivity depends on the time point of the first serum and on the availability of paired sera (for seroconversion and/or rise in titer); - "Gold standard": fourfold titer increase as measured in paired sera.
                                                       Immunoblotting                                                                                                                                                                                                                                       High sensitivity, high specificity                     AD      \- Confirmatory assay ([@B29]).
                                                       Immunofluorescent assay (IFA)                                                                                                                                                                                                                        Less sensitive and less specific than EIA              AD      \- Subjective interpretation.
                                                                                                                                                                                                                                                                                                                                                                           

Adapted from

Meyer Sauteur et al. (2014b)

. AD, advanced diagnostic test; CFT, complement fixation test; CSF, cerebrospinal fluid; EIA, enzyme immunoassay; IFA, immunofluorescent assay; Ig, immunoglobulin; PA, particle agglutination assay; PCR, polymerase chain reaction; RD, routine diagnostic test; RepMP, repeated M. pneumoniae DNA.

1

Largely replaced by EIA;

2

For the evaluation of an intrathecal antibody synthesis (

Granerod et al., 2010

), either by calculation of an antibody index (

Reiber, 1994

) or through parallel immunoblotting of simultaneously collected CSF and serum samples (

Monteyne et al., 1997

).

Current guidelines ([@B12]; [@B45]) recommend PCR and single-sample serological tests to diagnose *M. pneumoniae* infections. The sensitivity of serological tests depends on the time point of the first serum and on the availability of paired sera for seroconversion to IgG and/or rise in antibody titer. Specific serum IgM emerges within 1 week after initial infection and about 2 weeks before IgG ([@B68]). Although specific serum IgA arises even earlier than IgM, it could be detected only in 2% of PCR-positive children with symptomatic respiratory tract infection ([@B89]). Cross-reactions with other pathogens and non-infectious disease has been described for CFT and particle agglutination assay, but also some EIAs lack the required sensitivity and specificity ([@B10]). Further, it is intriguing that the detection of IgM, as well as IgG and IgA by EIA could not discriminate between the asymptomatic and symptomatic groups of children ([@B89]). The demonstrated positive serological results in asymptomatic *M. pneumoniae* PCR-positive children (*n* = 66; IgM in 17%, IgG in 24%, and IgA in 6%) may simply reflect one or more previous encounters with *M. pneumoniae* and are not necessarily related to the presence of *M. pneumoniae* in the respiratory tract. Thus, it is questionable whether or not a positive result in these tests actually indicates the etiological role of *M. pneumoniae* in all cases. In that sense, the positive predictive value of these tests may be overestimated, whereas the negative predictive value may be acceptable ([@B12]).

The "gold standard" for diagnosis of *M. pneumoniae* infections is still considered to be a fourfold increase in antibody titer as measured in paired sera ([@B42]). However, the use of convalescent sera is not useful in clinical practice because it is too time-consuming and does not allow clinicians to initiate treatment protocols in a timely fashion. Clinicians therefore need to be aware of the implications and clinical significance of a positive PCR or serology test result.

Clinical Assessment
-------------------

While diagnostic tests may not be reliably predictive for a symptomatic *M. pneumoniae* infection, the clinical assessment of this entity is being revisited. The British Thoracic Society guidelines recommend that bacterial pneumonia should be considered in children when there is persistent or repetitive fever \>38.5°C together with chest recession and a raised respiratory rate ([@B45]). A chest radiograph should not be considered a routine investigation in children thought to have CAP. In fact, although bilateral, diffuse infiltrates are common, none of the radiographic findings associated with *M. pneumoniae* CAP is specific ([@B52]).

A fast-and-frugal clinical decision tree provided a rapid probability estimate of the cause of CAP in 253 children (1 months--16 years; 1997--1999, Zurich, Switzerland) ([@B37]). *M. pneumoniae* infection was diagnosed in 13% (*n* = 32) of these children by PCR in respiratory specimens and serology (seroconversion and/or fourfold rise in antibody titer). Compared with other children with CAP, patients with *M. pneumoniae* were older and had a longer duration of fever (*p* \< 0.001). Asking the simple question regarding the age of the child and the duration of fever allowed identification of the following group at high risk for CAP due to *M. pneumoniae*: children with CAP who have had fever \>2 days and who were \>3 years of age. The score model placed 75% of all patients with *M. pneumoniae* infection into the high-risk group (**Figure [5](#F5){ref-type="fig"}**). These simple rules may further aid physicians in prescribing appropriate first-line antibiotics.

![**A fast-and-frugal clinical decision tree for ruling out *M. pneumoniae* infection in children with community-acquired pneumonia (CAP).** Clinical features are considered sequentially, with a possible stop decision after each question. Abbreviations: AR, absolute risk; CI, confidence interval. Adapted from [@B37].](fmicb-07-00329-g005){#F5}

Treatment And Vaccines
======================

Antibiotics
-----------

In consequence of the diagnostic uncertainty for *M. pneumoniae* infections, the British Thoracic Society guidelines suggest empiric macrolide treatment at any age if there is no response to first-line β-lactam antibiotics or in the case of very severe disease ([@B45]). The lack of a cell wall makes *M. pneumoniae* resistant to cell wall synthesis inhibitors such as β-lactam antibiotics. The antibiotics with the best minimum inhibitory concentration values against *M. pneumoniae* include macrolides, tetracyclines, and fluoroquinolones ([@B94]). Although the latter two have a good *in vitro* inhibitory effect against *M. pneumoniae*, tetracyclines may cause teeth discoloration ([@B94]) and fluoroquinolones may affect the developing cartilage in young children ([@B1]). Thus, they are not recommended by current guidelines in young children; the age limit for tetracyclines is ≥8 years, while that of fluoroquinolones is adolescence with skeletal maturity ([@B12]). The occurrence of arthropathy due to fluoroquinolones, however, is uncertain, and all musculoskeletal adverse effects reported in the literature had been reversible following withdrawal of treatment ([@B1]). The protein synthesis inhibitors of the macrolide class have a more favorable side effect profile and are therefore the first-line antibiotics for *M. pneumoniae* infections in children ([@B12]).

Although antibiotics are effective against *M. pneumoniae in vitro* ([@B7]), there is lack of evidence on their *in vivo* efficacy. Observational data indicated that children with CAP due to *M. pneumoniae* have a shorter duration of symptoms and fewer relapses when treated with an antimicrobial agent active against *M pneumoniae* ([@B61]; [@B94]). A recent Cochrane review evaluated seven studies on the effectiveness of antibiotic treatment for *M. pneumoniae* lower respiratory tract infections in children ([@B42]). However, the diagnostic criteria, the type and duration of treatment, inclusion criteria, and outcome measures differed significantly, making it difficult to draw any specific conclusions, although one trial suggested that macrolides may be efficacious in some cases ([@B34]). It is clear that studies on the efficacy of antibiotics rely on a correct diagnosis of *M. pneumoniae* infections. Given the aforementioned shortcomings of current diagnostic tests, conclusions on the efficacy of antibiotic treatment will have to be re-examined.

Antibiotic Resistance
---------------------

Since 2000, the extensive macrolide use led to an alarming worldwide increase in the prevalence of macrolide-resistant *M. pneumoniae* (MRMP) strains ([@B7]). Resistance is based on specific point mutations in domain V of the *23S rRNA* (at positions 2063, 2064, and 2617), which reduce the affinity of macrolides to the large subunit (50S) of the bacterial ribosome ([@B7]). MRMP has been observed during macrolide treatment as a result of antibiotic selective pressure ([@B15]; [@B23]; [@B84]). To date, macrolide resistance has been detected on a worldwide scale. MRMP had developed in Asia ([@B48]), where MRMP rates have risen as high as 97% in China ([@B98]). MRMP has now also been reported from North America and Europe (**Figure [6](#F6){ref-type="fig"}**).

![**Worldwide macrolide-resistant *M. pneumoniae* (MRMP) rates.** Actual MRMP rates are punctually depicted in pie charts (in black) over the world map. **Asia:** Japan (2011): 87% (176/202) ([@B79]), South Korea (2011): 63% (44/70) ([@B48]), China (2012): 97% (31/32) ([@B98]), Israel (2010): 30% (9/30) ([@B5]); **North America:** U.S. (2012--2014): 13% (12/91) ([@B99]), Canada (2010--2012): 12% (11/91) ([@B32]); **Europe:** The Netherlands (1997--2008): 0% (0/114) ([@B90]), Germany (2003--2008): 1% (2/167) ([@B30]), France (2005--2007): 10% (5/51) ([@B80]), Italy (2010): 26% (11/43) ([@B23]), Scotland (2010--2011): 19% (6/32) ([@B36]), Switzerland (2011--2013): 2% (1/50) ([@B64]), England and Wales (2014--2015): 9% (4/43) ([@B13]).](fmicb-07-00329-g006){#F6}

The clinical relevance of macrolide resistance in hospitalized children with CAP may lie in prolonging the symptoms of the disease ([@B79]; [@B14]; [@B100]). [@B100] found that an increase in MRMP may also have serious clinical consequences in children, leading to more severe radiological findings of CAP and even an increase in extrapulmonary manifestations. In this study, hospitalized children with CAP due to MRMP developed more often extrapulmonary disease than children with CAP caused by macrolide-sensitive strains (30% vs. 10%; *p* = 0.03) ([@B100]). These manifestations included skin diseases and nervous system complications in 18% and 7%, respectively, of the MRMP-infected children. Serum inflammatory cytokine levels (INF-γ, IL-6, and IP-10) were higher in patients infected with MRMP than in patients infected with macrolide-sensitive strains ([@B59]). This suggests that the higher and more persistent inflammatory stimulation by MRMP may increase the possibility of severe lung lesions and extrapulmonary complications.

Vaccines
--------

While previous attempts to produce vaccines on the basis of inactivated bacteria resulted in limited efficacy against CAP and various adverse effects ([@B57]), the recent use of recombinant proteins as potential vaccines was found to be promising: The immunization of mice with a immunogenic recombinant protein encompassing the C-terminal part of the P1 protein (RP14) induced strong mucosal and systemic antibody responses against *M. pneumoniae*, and reduced lung inflammation in infected mice ([@B101]). Another study showed that immunization of guinea pigs with a chimeric protein consisting of RP14 and the P30 adhesion protein of *M. pneumoniae* resulted in a robust antibody response that led to a reduction in bacterial loads in the respiratory tract ([@B46]).

Conclusion
==========

The increasing prevalence of MRMP has become a significant issue, since MRMP can potentially cause more severe and even extrapulmonary disease. Because symptoms and radiologic features of *M. pneumoniae* CAP seem to be unspecific and current diagnostic procedures cannot discern between carriage and infection in a clinically relevant time frame, simple clinical rules may further aid physicians in prescribing appropriate first-line antibiotics. Thus, empiric macrolide treatment may be restricted to children at high risk for *M. pneumoniae* CAP, i.e., children with CAP who have fever \>2 days and who are \>3 years of age, or in the case of very severe disease. Future research should focus on novel aspects of *M. pneumoniae-*related pathogenesis resulting in more precise diagnostic tools and tailored treatment that prevents the emergence of antimicrobial resistance.
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